ISS Stage III Plasma Cell Myeloma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which ISS Stage III Plasma Cell Myeloma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT02727803

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in trea…

United States100 participantsStarted 2016-05-19

Treatment: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin

All recent trials (5 shown)

Active — Not RecruitingPhase 2

NCT05497804

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, s…

United States17 participantsStarted 2022-09-22

Treatment: Bone Marrow Aspiration and Biopsy, Carfilzomib

CompletedPhase 1/2

NCT03267888

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come b…

United States25 participantsStarted 2018-05-29

Treatment: Pembrolizumab, Radiation Therapy

ISS Stage III Plasma Cell Myeloma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Personalized NK Cell Therapy in CBT

All recent trials (5 shown)

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Personalized NK Cell Therapy in CBT

All recent trials (5 shown)

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NK Cells in Cord Blood Transplantation